Vaccinex, Inc.

VCNX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017
Revenue $90.0K
Cost of Revenue $160.0K
Gross Profit $-70.0K
Gross Margin -77.8%
Operating Expenses
Research & Development $16.6M
SG&A Expense $4.5M
Operating Income $-21.1M
Operating Margin -23,448.9%
Interest Expense $1.4M
Pretax Income $-18.8M
Income Tax Expense $0
Net Income $-18.7M
Net Margin -20,802.2%
EPS (Basic) $-3.98
EPS (Diluted) $-3.98
Shares Outstanding (Basic) 5.5M
Shares Outstanding (Diluted) 5.5M
Dividends Per Share
← Newer Page 2 of 2 Older →